HC Wainwright Has Positive View of BioCardia FY2024 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for BioCardia in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($3.52) for the year, up from their previous forecast of ($5.06). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.03) EPS.

BioCardia Stock Performance

Shares of NASDAQ:BCDA opened at $2.03 on Monday. The business’s 50 day simple moving average is $2.56 and its two-hundred day simple moving average is $3.25. The firm has a market cap of $4.31 million, a P/E ratio of -0.48 and a beta of 1.28. BioCardia has a 52-week low of $1.84 and a 52-week high of $11.55.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.